Where I see patients (1)
Selected research
-
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.
Blood
-
Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.
Future oncology (London, England)
-
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1.
Blood advances